# Evaluation of Dupilumab in Children With Uncontrolled Asthma

> **NCT02948959** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 408 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Asthma Controller Therapies
- **DRUG:** Asthma Reliever Therapies

## Key facts

- **NCT ID:** NCT02948959
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-21
- **Primary completion:** 2020-08-26
- **Final completion:** 2020-08-26
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948959, "Evaluation of Dupilumab in Children With Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02948959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*